BAO PHARMA-B's stock plummeted 64.33% during intraday trading on Thursday, marking a severe decline for the biotechnology company.
The sharp drop followed the release of the company's annual report, which disclosed that net losses attributable to shareholders widened to RMB 395 million from RMB 364 million in the prior year, despite a significant 697.99% year-over-year surge in revenue. This deterioration in profitability likely triggered investor concern and a sell-off.
The stock's performance contrasted with mixed movements in the broader biotechnology sector during the session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments